Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc. on March 20, 2026. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on The Nasdaq Capital Market under the symbol "ALZN". The filing addresses a regulatory notice received from Nasdaq regarding the Company's continued listing status.
Key Financial Metrics
The filing references financial data from the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026.
- Stockholders' Equity: Approximately $2.2 million as of January 31, 2026.
- Revenue: The filing states there is an absence of any significant revenue generated from the Company's core business of the nascent Bitnile.com platform.
- Cash Flow: The Company expects to continue to incur significant losses and negative cash flow.
- Debt and Liquidity: Specific debt figures and liquidity ratios are not provided in this filing text.
Material Changes and Listing Status
On March 20, 2026, the Company received a letter from the Nasdaq Listing Qualifications staff indicating non-compliance with Nasdaq Listing Rule 5550(b)(1). This rule requires a minimum stockholders' equity of $2.5 million for continued listing on the Nasdaq Capital Market. As the Company's equity was reported at approximately $2.2 million, it failed to meet this threshold. The letter has no immediate effect on the trading of the Company's common stock.
Outlook, Risks, and Management Commentary
Compliance Plan: The Company has an initial period of 45 calendar days, until May 4, 2026, to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant up to 180 calendar days (until September 16, 2026) to evidence compliance.
Risks and Contingencies:
- There is no assurance that the Company's compliance plan will be accepted or that it will successfully regain compliance.
- If the plan is rejected or compliance is not achieved within the allowed timeframe, the Company's stock could be subject to delisting.
- The Company retains the right to appeal a delisting determination to a Nasdaq Hearings Panel, which would stay any suspension pending the hearing.
- Significant risks include the need for additional funding which may not be available, continued significant losses, and the evolving business model with no significant revenue from the Bitnile.com platform.
Investor Verification Checklist
- Verify the specific details of the compliance plan the Company intends to submit by May 4, 2026.
- Review the most recent Form 10-Q (ended January 31, 2026) for detailed financial statements regarding the $2.2 million equity position.
- Monitor announcements regarding the acceptance or rejection of the compliance plan by Nasdaq.
- Assess the Company's capital raise efforts given the stated need for additional funding and negative cash flow.
- Check for any updates on the revenue generation status of the Bitnile.com platform.